--- title: "Filana Therapeutics (FLNA) news: class action and offering" url: "https://aibio.space/companies/filana-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FLNA class action, offering and settlement news: Fifth Circuit vacates class certification in Filana securities class action. Filana Therapeutics, Inc." --- FLNA Filana Therapeutics, Inc. NASDAQ · United States # Filana Therapeutics (FLNA) news FLNA class action, offering and settlement news Legal · 2026-10-20 ## [Fifth Circuit vacates class certification in Filana securities class action](https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/) The appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it. ## Latest Filana Therapeutics news 1. 2026-09-18 Listings [Filana Therapeutics gets Nasdaq bid price notice, has until March 16, 2027](https://aibio.space/news/filana-therapeutics-gets-nasdaq-bid-price-notice-has-until-march-16/) Nasdaq gives Filana until March 16, 2027 to regain compliance. Cash and equivalents fell to $86.6 million at March 31, 2026, from $128.6 million at the end of 2024. 2. 2025-12-23 Legal [Cassava Sciences (now Filana Therapeutics) agrees to $31.25 million class action settlement](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-agrees-31-25-million-class/) Cassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves. 3. 2025-11-13 Financings [Cassava Sciences (now Filana Therapeutics) files $200,000,000 shelf, $50,000,000 ATM](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-files-200-000-000-shelf-50/) The at-the-market supplement lets Cantor Fitzgerald sell up to $50,000,000 of stock for up to 3.0% in commissions. The company's lead drug failed its Phase 3 Alzheimer's study, and its share price closed at $3.11. 4. 2025-01-07 Distress [Cassava Sciences (now Filana Therapeutics) cuts 33% of workforce, reports $128.6 million cash](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-33-percent-workforce/) After its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024. 5. 2025-01-07 Distress [Cassava Sciences (now Filana Therapeutics) cuts workforce by about 33%, reports $128.6 million cash](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-workforce-about-33/) The Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing. ## Filana Therapeutics at a glance - **Ticker**: FLNA - **Listing**: NASDAQ - **Country**: United States - **Cash, Mar 31, 2026**: $86.6 million ### Related companies - [Tango Therapeutics](https://aibio.space/companies/tango-therapeutics/) NASDAQ: TNGX - [Nurix Therapeutics](https://aibio.space/companies/nurix-therapeutics/) NASDAQ: NRIX - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) NASDAQ: HALO - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [Vistagen Therapeutics](https://aibio.space/companies/vistagen-therapeutics/) NASDAQ: VTGN - [Xencor](https://aibio.space/companies/xencor/) NASDAQ: XNCR - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Equillium](https://aibio.space/companies/equillium/) NASDAQ: EQ ### Also on NASDAQ - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) OVID - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) SKYE - [Baird Medical Investment Holdings](https://aibio.space/companies/baird-medical-investment/) BDMD - [AnaptysBio](https://aibio.space/companies/anaptysbio/) ANAB - [Neuronetics](https://aibio.space/companies/neuronetics/) STIM - [Genelux](https://aibio.space/companies/genelux/) GNLX ## What Filana Therapeutics does Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company based in Austin, Texas. Its mission is to develop medicines for central nervous system disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases linked to dysregulation or overexpression of filamin A. Its lead candidate, simufilam, is a small-molecule oral treatment being studied for TSC-related epilepsy. Simufilam is designed to modulate filamin A, a protein that regulates neuronal cell development. The company describes it as a potential first-in-class filamin A-modulating agent. Clinical trials of simufilam in Alzheimer's disease, including two Phase 3 studies, were discontinued in 2024, and the phase-out of that program was completed in the second quarter of 2025. The company says it owns or controls worldwide rights to simufilam, including nine issued U.S. patents with expiration dates from 2029 to 2040, and holds an exclusive worldwide license from Yale University to certain related patent rights. Preclinical work suggests possible benefit in other indications. | Product or program | What it is | Stage | |---|---|---| | Simufilam | Small-molecule oral filamin A modulator for TSC-related epilepsy | clinical; TSC-related epilepsy | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/sava20251231_10k.htm). ## Filana Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$26.6 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | [$69.6 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | | Net income (loss) | [-$91.0 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | [-$24.3 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | | Cash from operations | [-$32.3 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | [-$116.9 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | | Cash and equivalents | [$95.5 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926015664/) | [$128.6 million](https://www.sec.gov/Archives/edgar/data/1069530/000143774926007962/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $86.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Filana Therapeutics Is there a class action against Filana Therapeutics? Our latest story on this, dated Oct 20, 2026: "Fifth Circuit vacates class certification in Filana securities class action". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/). Has Filana Therapeutics raised money recently? Our latest story on this, dated Nov 13, 2025: "Cassava Sciences (now Filana Therapeutics) files $200,000,000 shelf, $50,000,000 ATM". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-files-200-000-000-shelf-50/). Has Filana Therapeutics settled a lawsuit? Our latest story on this, dated Oct 20, 2026: "Fifth Circuit vacates class certification in Filana securities class action". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/). What is the ticker symbol of Filana Therapeutics? Filana Therapeutics, Inc. trades under the ticker FLNA on NASDAQ. Where is Filana Therapeutics listed? Filana Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BMV:FLNA; GETTEX:PX91; LS:A2PGL8; LSX:A2PGL8. What is the SEC CIK of Filana Therapeutics? The SEC Central Index Key (CIK) for Filana Therapeutics, Inc. is 1069530. Its filings are on SEC EDGAR. Which country or territory is Filana Therapeutics listed under? Our directory records Filana Therapeutics, Inc. under United States. What does Filana Therapeutics do? Our directory classifies Filana Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Filana Therapeutics? The ISIN recorded for Filana Therapeutics, Inc. is US14817C1071. Does aibio.space cover Filana Therapeutics? aibio.space lists Filana Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Filana Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Filana Therapeutics develop? Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company based in Austin, Texas. Its mission is to develop medicines for central nervous system disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases linked to dysregulation or overexpression of filamin A. Its lead candidate, simufilam, is a small-molecule oral treatment being studied for TSC-related epilepsy. What is Simufilam from Filana Therapeutics? Simufilam: Small-molecule oral filamin A modulator for TSC-related epilepsy Stage: clinical; TSC-related epilepsy. Is Filana Therapeutics profitable? Filana Therapeutics, Inc. reported a net loss of $91.0 million for the fiscal year ended Dec 31, 2025, and used $32.3 million of cash in operations, per its annual report to the SEC. How much does Filana Therapeutics spend on research and development? $26.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Filana Therapeutics Members talk about Filana Therapeutics (FLNA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Filana Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1069530/000143774926032971/sava20261019_8k.htm) 2. 2026-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1069530/000143774926030751/sava20260918_8k.htm) 3. 2025-11-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1069530/000149315225022066/forms-3.htm) 4. 2025-01-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FLNA on TradingView](https://www.tradingview.com/symbols/NASDAQ-FLNA/). ## SEC filings and registration - **SEC name**: Filana Therapeutics, Inc. - **CIK**: 1069530 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: FLNA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731 - **Phone**: 512-501-2444 - **Former names**: CASSAVA SCIENCES INC; PAIN THERAPEUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774926032971/sava20261019_8k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000117184326006161/f8k_092226.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774926030751/sava20260918_8k.htm) filed 2026-09-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/sava20260630_10q.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/f8k_072826.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/sava20260610_8k.htm) filed 2026-06-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1069530/000143774926015664/sava20260331_10q.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/f8k_050726.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001069530), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Filana Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FLNA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Filana Therapeutics, Inc. - **Ticker**: FLNA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US14817C1071 - **Other listed symbols**: BMV:FLNA; GETTEX:PX91; LS:A2PGL8; LSX:A2PGL8 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FLNA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/filana-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Filana Therapeutics (FLNA) news: class action and offering", 2026-10-31, https://aibio.space/companies/filana-therapeutics/